vs

Side-by-side financial comparison of SYPRIS SOLUTIONS INC (SYPR) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

SYPRIS SOLUTIONS INC is the larger business by last-quarter revenue ($30.3M vs $27.6M, roughly 1.1× Zymeworks Inc.). SYPRIS SOLUTIONS INC runs the higher net margin — -12.9% vs -71.0%, a 58.1% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs -9.5%). SYPRIS SOLUTIONS INC produced more free cash flow last quarter ($-1.5M vs $-31.8M).

Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

SYPR vs ZYME — Head-to-Head

Bigger by revenue
SYPR
SYPR
1.1× larger
SYPR
$30.3M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+82.1% gap
ZYME
72.6%
-9.5%
SYPR
Higher net margin
SYPR
SYPR
58.1% more per $
SYPR
-12.9%
-71.0%
ZYME
More free cash flow
SYPR
SYPR
$30.3M more FCF
SYPR
$-1.5M
$-31.8M
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
SYPR
SYPR
ZYME
ZYME
Revenue
$30.3M
$27.6M
Net Profit
$-3.9M
$-19.6M
Gross Margin
4.6%
Operating Margin
-10.9%
-80.1%
Net Margin
-12.9%
-71.0%
Revenue YoY
-9.5%
72.6%
Net Profit YoY
-2992.6%
34.3%
EPS (diluted)
$-0.17
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SYPR
SYPR
ZYME
ZYME
Q4 25
$30.3M
Q3 25
$28.7M
$27.6M
Q2 25
$31.4M
$48.7M
Q1 25
$29.5M
$27.1M
Q4 24
$33.4M
$31.0M
Q3 24
$35.7M
$16.0M
Q2 24
$35.5M
$19.2M
Q1 24
$35.6M
$10.0M
Net Profit
SYPR
SYPR
ZYME
ZYME
Q4 25
$-3.9M
Q3 25
$517.0K
$-19.6M
Q2 25
$-2.1M
$2.3M
Q1 25
$-899.0K
$-22.6M
Q4 24
$135.0K
$-23.5M
Q3 24
$390.0K
$-29.9M
Q2 24
$16.0K
$-37.7M
Q1 24
$-2.2M
$-31.7M
Gross Margin
SYPR
SYPR
ZYME
ZYME
Q4 25
4.6%
Q3 25
7.2%
Q2 25
8.2%
Q1 25
11.4%
Q4 24
16.1%
Q3 24
16.8%
Q2 24
15.9%
Q1 24
8.1%
Operating Margin
SYPR
SYPR
ZYME
ZYME
Q4 25
-10.9%
Q3 25
-6.1%
-80.1%
Q2 25
-4.6%
-1.4%
Q1 25
-0.4%
-94.5%
Q4 24
3.9%
-71.6%
Q3 24
4.8%
-213.8%
Q2 24
3.6%
-222.9%
Q1 24
-3.9%
-376.9%
Net Margin
SYPR
SYPR
ZYME
ZYME
Q4 25
-12.9%
Q3 25
1.8%
-71.0%
Q2 25
-6.5%
4.8%
Q1 25
-3.0%
-83.5%
Q4 24
0.4%
-75.8%
Q3 24
1.1%
-186.6%
Q2 24
0.0%
-195.8%
Q1 24
-6.2%
-315.6%
EPS (diluted)
SYPR
SYPR
ZYME
ZYME
Q4 25
$-0.17
Q3 25
$0.02
$-0.26
Q2 25
$-0.09
$0.03
Q1 25
$-0.04
$-0.30
Q4 24
$0.00
$-0.32
Q3 24
$0.02
$-0.39
Q2 24
$0.00
$-0.49
Q1 24
$-0.10
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SYPR
SYPR
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$17.8M
$320.1M
Total Assets
$107.8M
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SYPR
SYPR
ZYME
ZYME
Q4 25
Q3 25
$64.8M
Q2 25
$98.3M
Q1 25
$76.2M
Q4 24
$66.1M
Q3 24
$122.4M
Q2 24
$71.0M
Q1 24
$114.8M
Stockholders' Equity
SYPR
SYPR
ZYME
ZYME
Q4 25
$17.8M
Q3 25
$20.0M
$320.1M
Q2 25
$18.7M
$334.5M
Q1 25
$19.0M
$325.0M
Q4 24
$19.6M
$338.8M
Q3 24
$18.2M
$367.0M
Q2 24
$19.0M
$406.2M
Q1 24
$20.8M
$438.0M
Total Assets
SYPR
SYPR
ZYME
ZYME
Q4 25
$107.8M
Q3 25
$112.5M
$397.3M
Q2 25
$105.8M
$408.4M
Q1 25
$110.2M
$425.5M
Q4 24
$119.4M
$463.1M
Q3 24
$121.6M
$487.2M
Q2 24
$124.2M
$515.6M
Q1 24
$129.0M
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SYPR
SYPR
ZYME
ZYME
Operating Cash FlowLast quarter
$-1.1M
$-31.4M
Free Cash FlowOCF − Capex
$-1.5M
$-31.8M
FCF MarginFCF / Revenue
-5.0%
-115.2%
Capex IntensityCapex / Revenue
1.3%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-6.5M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SYPR
SYPR
ZYME
ZYME
Q4 25
$-1.1M
Q3 25
$-178.0K
$-31.4M
Q2 25
$1.1M
$12.1M
Q1 25
$-5.5M
$-3.4M
Q4 24
$2.3M
$-41.5M
Q3 24
$-4.8M
$-5.9M
Q2 24
$6.2M
$-25.0M
Q1 24
$-1.7M
$-37.7M
Free Cash Flow
SYPR
SYPR
ZYME
ZYME
Q4 25
$-1.5M
Q3 25
$-390.0K
$-31.8M
Q2 25
$941.0K
$11.6M
Q1 25
$-5.5M
$-3.4M
Q4 24
$1.9M
$-41.8M
Q3 24
$-4.9M
$-6.8M
Q2 24
$6.0M
$-25.6M
Q1 24
$-2.0M
$-37.9M
FCF Margin
SYPR
SYPR
ZYME
ZYME
Q4 25
-5.0%
Q3 25
-1.4%
-115.2%
Q2 25
3.0%
23.7%
Q1 25
-18.8%
-12.6%
Q4 24
5.7%
-134.8%
Q3 24
-13.8%
-42.4%
Q2 24
16.8%
-133.0%
Q1 24
-5.7%
-377.5%
Capex Intensity
SYPR
SYPR
ZYME
ZYME
Q4 25
1.3%
Q3 25
0.7%
1.5%
Q2 25
0.5%
1.1%
Q1 25
0.0%
0.1%
Q4 24
1.2%
1.0%
Q3 24
0.4%
5.6%
Q2 24
0.5%
3.1%
Q1 24
0.9%
1.8%
Cash Conversion
SYPR
SYPR
ZYME
ZYME
Q4 25
Q3 25
-0.34×
Q2 25
5.21×
Q1 25
Q4 24
17.13×
Q3 24
-12.21×
Q2 24
385.25×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SYPR
SYPR

Sypris Electronics$17.7M59%
Transferred At Point In Time$12.5M41%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons